drugset / Trial / NCT00694707

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

NCT00694707 ↗

Phase 2 Completed 732 enrolled Forest Laboratories Gedeon Richter Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.

Timeline

Start
2008-06-30
Primary completion
2009-08-31
Completion
2009-08-31

Outcome

Met primary endpoint

registry analysis (superiority or other test); Placebo vs Cariprazine 1.5 mg; p = 0.0005; Least squares mean difference -7.5 (95% CI -11.8 to -3.3); ANCOVA NCT00694707 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 1.5 mg Oral
Subject Cariprazine Small molecule 3 mg Oral
Subject Cariprazine Small molecule 4.5 mg Oral
Comparator Risperidone Other / unclassified 4 mg Oral

Indications